Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536809 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00536809 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 12 participants.
The verdict
NCT00536809, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs in subjects with previously untreated advanced or metastatic colorectal cancer.
Interventions
- DRUG oxaliplatin
- DRUG capecitabine
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-09-26 |
| Est. Completion | 2008-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00536809
The ClinicalTrials.gov registry entry for NCT00536809 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which oxaliplatin is the first listed.
NCT00536809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00536809 about?
NCT00536809 is a clinical study titled "Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer". The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs in subjects with previously untreated advanced or metastatic colorecta...
What is the current status of trial NCT00536809?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2007-09-26. Estimated completion is 2008-10-31.
What interventions are being tested in trial NCT00536809?
The interventions under investigation include: oxaliplatin (DRUG), capecitabine (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00536809?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.